Prevents pregnancy. ANDA 207506, held by Aurobindo Pharma. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 207506 (Aurovela 1/20), held by Aurobindo Pharma, was first approved by FDA on Jun 16, 2017, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Aurovela 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE 1 LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD Adapted from RA Hatcher et al, Reference 7.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 16, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aurovela 1/200.02MG;1MG · tablet;oral-21 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Mar 28, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 28, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 28, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 16, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters